Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

It can be used against a list of HRT products, including patches, tablets and topical preparations. According to the data, ...

The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal ...

Sadeq Ali Quraishi, MD, a former Tufts Medical Center anesthesiologist, has been convicted of attempted sex trafficking of a ...

Both trials met their primary endpoints, indicating a significant improvement in patients treated with the drug.

GSK announces positive phase III results from ANCHOR trials for depemokimab in chronic rhinosinusitis with nasal polyps: London, UK Tuesday, October 15, 2024, 10:00 Hrs [IST] GSK ...

GSK announced positive results from two phase 3 clinical trials evaluating its experimental drug, depemokimab, for chronic rhinosinusitis with nasal polyps affecting 4% of the population.

TI Fluid, which makes fluid systems for the likes of Aston Martin, Porsche and Fiat, said it has received a fifth takeover ...

The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.

GSK announced another batch of positive data from its respiratory program with the investigational drug depemokimab, this ...

UK pharma major GSK today announced positive headline results from two Phase III clinical trials, ANCHOR-1 and ANCHOR-2, ...

Ceiling prices were also revised for the asthma drug Salbutamol in tablets of 2 mg and 4 mg formulations and respirator ...